TY - JOUR
T1 - INCREASING EVIDENCE FOR THE SAFETY OF FOVEA-INVOLVING HALF-DOSE PHOTODYNAMIC THERAPY FOR CHRONIC CENTRAL SEROUS CHORIORETINOPATHY
AU - Feenstra, Helena M. A.
AU - Diederen, Roselie M. H.
AU - Lamme, Martine J. C. M.
AU - Tsonaka, Roula
AU - Fauser, Sascha
AU - Yzer, Suzanne
AU - van Rijssen, Thomas
AU - Gkika, Theodora
AU - Downes, Susan M.
AU - Schlingemann, Reinier O.
AU - Hoyng, Carel B.
AU - van Dijk, Elon H. C.
AU - Boon, Camiel J. F.
N1 - Funding Information: H. M. A. Feenstra was supported by the Blindenhulp Fellowship from Stichting Blindenhulp (The Hague, the Netherlands). This research was also supported by the following foundations: Stichting Ooglijders (Rotterdam, the Netherlands); Stichting Macula Fonds; Retina Nederland Onderzoek Fonds; Stichting Blinden-Penning; Algemene Nederlandse Vereniging ter Voorkoming van Blindheid; Landelijke Stichting voor Blinden en Slechtzienden, which contributed through UitZicht (Delft, the Netherlands); Rotterdamse Stichting Blindenbelangen (Rotterdam, the Netherlands); Stichting Leids Oogheelkundig Ondersteuningsfonds (Leiden, the Netherlands); the Oxford NIHR Biomedical Research Center (Oxford, United Kingdom); the Gisela Thier Fellowship of Leiden University (Leiden, the Netherlands [C. J. F. Boon]); and the Netherlands Organization for Scientific Research (VENI grant to C. J. F. Boon). These funding organizations provided unrestricted grants and had no role in the design or conduct of this research. This investigator-initiated study received funding from Novartis Pharma B.V. (Arnhem, the Netherlands) solely for the purchase of verteporfin (Visudyne) to enable half-dose photodynamic therapy treatment at the Oxford site because photodynamic therapy currently is not reimbursed routinely by the U.K. National Health Service for treating central serous chorioretinopathy. Novartis Pharma B.V. had no role in funding, designing, conducting, or evaluating the study, nor in the writing of this manuscript. Funding Information: H. M. A. Feenstra was supported by the Blindenhulp Fellowship from Stichting Blindenhulp (The Hague, the Netherlands). This research was also supported by the following foundations: Stichting Ooglijders (Rotterdam, the Netherlands); Stichting Macula Fonds; Retina Nederland Onderzoek Fonds; Stichting Blinden-Penning; Algemene Nederlandse Vereniging ter Voorkoming van Blindheid; Landelijke Stichting voor Blinden en Slechtzienden, which contributed through UitZicht (Delft, the Netherlands); Rotterdamse Stichting Blindenbelangen (Rotterdam, the Netherlands); Stichting Leids Oogheelkundig Ondersteuningsfonds (Leiden, the Netherlands); the Oxford NIHR Biomedical Research Center (Oxford, United Kingdom); the Gisela Thier Fellowship of Leiden University (Leiden, the Netherlands [C. J. F. Boon]); and the Netherlands Organization for Scientific Research (VENI grant to C. J. F. Boon). These funding organizations provided unrestricted grants and had no role in the design or conduct of this research. This investigator-initiated study received funding from Novartis Pharma B.V. (Arnhem, the Netherlands) solely for the purchase of verteporfin (Visudyne) to enable half-dose photodynamic therapy treatment at the Oxford site because photodynamic therapy currently is not reimbursed routinely by the U.K. National Health Service for treating central serous chorioretinopathy. Novartis Pharma B.V. had no role in funding, designing, conducting, or evaluating the study, nor in the writing of this manuscript. Publisher Copyright: Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2023/3/1
Y1 - 2023/3/1
N2 - Purpose:A retrospective study was performed with data from the prospective randomized controlled trials, PLACE and SPECTRA, assessing the risk of foveal atrophy and the likelihood of structural and functional improvement on optical coherence tomography, after foveal half-dose photodynamic therapy in chronic central serous chorioretinopathy.Methods:A total of 57 chronic central serous chorioretinopathy patients received a single half-dose photodynamic therapy with a treatment spot that included the fovea. Optical coherence tomography scans and fundus autofluorescence images were analyzed for structural improvement and possible atrophy development, at baseline and at several visits after treatment. Main outcome measures were integrity of the external limiting membrane and ellipsoid zone on optical coherence tomography and hypoautofluorescence on fundus autofluorescence.Results:The subfoveal external limiting membrane was graded as continuous in 21 of 57 of patients (36.8%) at baseline, and the subfoveal ellipsoid zone was graded as continuous in 5 of 57 patients (8.8%) at first visit, which improved to 50 of 51 (98.0%) and 32 out of 51 (62.7%) at the final visit at 2 years, respectively (both P < 0.001). Hypoautofluorescent changes on fundus autofluorescence were present in 25 of 55 patients (45.5%) at baseline and in 23 of 51 patients (45.1%) at the final visit (P = 0.480).Conclusion:In patients with chronic central serous chorioretinopathy who received a single, foveal, half-dose photodynamic therapy, a significant improvement in structure and function was seen at the final follow-up. None of the patients developed foveal atrophy.
AB - Purpose:A retrospective study was performed with data from the prospective randomized controlled trials, PLACE and SPECTRA, assessing the risk of foveal atrophy and the likelihood of structural and functional improvement on optical coherence tomography, after foveal half-dose photodynamic therapy in chronic central serous chorioretinopathy.Methods:A total of 57 chronic central serous chorioretinopathy patients received a single half-dose photodynamic therapy with a treatment spot that included the fovea. Optical coherence tomography scans and fundus autofluorescence images were analyzed for structural improvement and possible atrophy development, at baseline and at several visits after treatment. Main outcome measures were integrity of the external limiting membrane and ellipsoid zone on optical coherence tomography and hypoautofluorescence on fundus autofluorescence.Results:The subfoveal external limiting membrane was graded as continuous in 21 of 57 of patients (36.8%) at baseline, and the subfoveal ellipsoid zone was graded as continuous in 5 of 57 patients (8.8%) at first visit, which improved to 50 of 51 (98.0%) and 32 out of 51 (62.7%) at the final visit at 2 years, respectively (both P < 0.001). Hypoautofluorescent changes on fundus autofluorescence were present in 25 of 55 patients (45.5%) at baseline and in 23 of 51 patients (45.1%) at the final visit (P = 0.480).Conclusion:In patients with chronic central serous chorioretinopathy who received a single, foveal, half-dose photodynamic therapy, a significant improvement in structure and function was seen at the final follow-up. None of the patients developed foveal atrophy.
KW - adverse event
KW - chorioretinal atrophy
KW - chronic central serous chorioretinopathy
KW - foveal atrophy
KW - fundus autofluorescence
KW - optical coherence tomography
KW - photodynamic therapy
UR - http://www.scopus.com/inward/record.url?scp=85148678561&partnerID=8YFLogxK
U2 - https://doi.org/10.1097/IAE.0000000000003686
DO - https://doi.org/10.1097/IAE.0000000000003686
M3 - Article
C2 - 36727801
SN - 0275-004X
VL - 43
SP - 379
EP - 388
JO - Retina (Philadelphia, Pa.)
JF - Retina (Philadelphia, Pa.)
IS - 3
ER -